Interstitial Lung Diseases in the Veterans Administration

Interstitial Lung Disease Clinical Trial

Official title:

Interstitial Lung Diseases in the Veterans Administration Health System - A Retrospective Description of Patient Characteristics, Management, and Outcomes

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02479126
• Other study ID #: 01882
• Status: Active, not recruiting
• Start date: July 2016
• Est. completion date: June 2023

Study information

• Verified date: July 2022
• Source: Durham VA Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The primary objective of this research project is to describe the characteristics, diagnosis, management, and outcomes of patients with Interstitial Lung Disease (ILD) who received care at the Veteran's Administration Veterans Integrated Service Network (VISN) 6 Mid-Atlantic Health Care Network (VISN6) (includes North Carolina, Virginia and West Virginia) for up to 5 years.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 3000
• Est. completion date: June 2023
• Est. primary completion date: November 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Interstitial Lung Disease (ILD) ICD-9 code diagnosis 515.0 or 516.3

Exclusion Criteria:

• Inadequate documentation of patient receiving care for ILD in the health records

Related Conditions & MeSH terms

• Interstitial Lung Disease
• Lung Diseases
• Lung Diseases, Interstitial

Locations

Country	Name	City	State
United States	Durham VA Medical Center	Durham	North Carolina

Sponsors (3)

Lead Sponsor	Collaborator
Robert Tighe	Boehringer Ingelheim, Durham VA Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Prevalence of Interstitial Lung Disease in the VISN6 Veterans Administration Patient Population		up to 5 years
Primary	Prevalence of Idiopathic Pulmonary Fibrosis in the VISN6 Veterans Administration Patient Population		up to 5 years
Secondary	Accuracy of ICD-9 Codes for diagnosis of Interstitial Lung Disease	Will compare the reported ICD-9 code diagnosis with the diagnosis made after chart review and re-interpretation of the lung imaging and pathology	up to 5 years
Secondary	Frequency of ICD-9 code diagnosis of Interstitial Lung Disease and clinic consultation with a pulmonary provider		up to 5 years
Secondary	Prevalence of Co-morbid Diabetes Mellitus with Interstitial Lung Disease	Compare the prevalence of diabetes with interstitial lung disease as compared to the prevalence of diabetes in the general VA population	up to five years